PTK2 and colorectal carcinoma: The potential downstream effectors and therapeutic targeting of the integrin‐FAK axis in CRC were assessed by analyses of functional and signaling effects of gene knockdown and pharmacological inhibitors alone or in combinations with chemotherapeutic agents across a panel of representative cell line models.